Barcelona The BioRegion of Catalonia - An expanding life sciences and healthcare startup ecosystem, based on world-class science, in a great city ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Barcelona The BioRegion of Catalonia An expanding life sciences and healthcare startup ecosystem, based on world-class science, in a great city.
Rapid investment growth in life sciences startups
600
x4
Grants
Private investment* Investment growth
500
in the last 5 years
(over the previous period)
400
300
200
A new company is
created every week 1/week
+€225M
100 Investment in life
sciences and healthcare
0
2011-2015 2016-2020 startups in 2020
Source: Biocat.
*Private investment = Venture Capital, Private Equity, Stock Market, Crowdequity.
Digital Health: A rapidly emerging subsector
X7
Total Funding Investment growth
100
in the last 5 years
(2016-2020)
80
X6
Digital Health
60
startups in the last
40 10 years
(2011-2020)
+€34M
20
Investment in Digital
0
2016-2018 2019-2021YTD* Health startups in 2020
Source: Biocat.
*2021YTD = April, 2021.
But the growth has only started
Total VC/PE investment ($M) in emerging life
sciences and healthcare startups (2016-2020)
A great 3.3x
investment
opportunity
Source: Crunchbase, report based on Seed, Venture Series, Angel, Crowdequity and Private Equity funding only.
A highly internationalized investment ecosystem
Cumulative number of foreign investors
73
in life sciences and healthcare startups
foreign VC/PE firms
70
60
investing in Barcelona
50
startups
57% from Europe (excl. Spain)
40 30% from North America
30
9% from Asia
4% Other
62%
20
10 of all investment in VC/PE
0 rounds include foreign firms
2015 2020
RECENT FOREIGN INVESTORS
Source: Biocat.
Barcelona, home to specialized investors
€700m
Raised by specialised firms in the BioRegion,
available for co-investment in the life sciences
OPEN FUNDS and healthcare
Find all angel investors, venture capital and private equity firms at: http://www.catalanlifesciences.com/
Source: Biocat.
A diverse life Biotechnology Medical Technology Digital Health
sciences and €30-150m invested €30-150m invested €30-150m invested
healthcare €15-30m invested
€15-30m invested
startup
landscape €5-15m invested €5-15m invested €5-15m invested
€1-5m invested €1-5m invested €1-5m invested
Source: Biocat. Investments between 2015 and 2020, both included.
A booming
Digital Health
ecosystem
+200
active companies
x2
(2014-2019)
Source: Biocat. Illustrative representation. Relevant companies may not have been detected. Please contact us if you would like your company registered at http://www.catalanlifesciences.com/.
+1,700 startups
1st Paris (all sectors) +500 in Biotech, Medtech and Digital Health
2nd Berlin
3rd
3rd Barcelona EU TECH HUB
4th Stockholm by funding rounds for startups
(all tech sectors, 2016-2020)
5th Amsterdam
Source: Barcelona & Catalonia Start-up Hub (ACCIO) and Dealroom
#10 Oulu
Barcelona, #2 Stockholm
5 th
most invested city in
Digital Health in Europe #6 Copenhagen
amid pandemic #1 London
#8 Amsterdam
(2020–April 2021) #3 Oxford
#4 Berlin
+ US$ 100 M
#7 Paris US$ 50-100 M
US$ 30-50 M
#9 Marseille
#5 BARCELONA
Source: Crunchbase, report based on Angel, Seed and Venture Capital Series funding only.Dublin Amsterdam Berlin
London
Barcelona,
2
Paris
most EU attractive city
nd
Munich Vienna
Zurich
for startup founders Milan
BARCELONA
Madrid
Lisbon
Source: Startup Heatmap Europe, 2021.4 th in the world by number of
international investments in R&D
Financial Times’ Southern Europe’s
TOP REGION
for foreign investment
Source: Global Cities Investment Monitor - FDi Markets Database, 2018 and FDi Markets Magazine, 2019.An opportunity to invest in world-class life sciences research & startups
1st Paris
2nd Londonc
3rd Zürich
4th Cambridge
5th Berlin
6th Munich
7th Oxford
8th Lausanne Nature Index
9th Barcelona SCIENCE CITIES IN EUROPE,
10th Madrid 40th in the world
11th Stockholm
12th Copenhaguen
13th Vienna
14th Heidelberg
15th Amsterdam
Source: Nature Index, 2020.With leading research centers,
companies, hospitals and
universities,
Catalonia produces high
quality life sciences and
healthcare research at a large
volume
Source: Scopus (Elsevier), SCIMAGO, SIRIS Academic. [Population] BEL=11,6M SWE=10M AUT= 9M CAT=7,5M DNK=5,8M FIN=5,5M IRL=4,9MCatalan institutions and companies
are very competitive in attracting EU
funding, which supports the best
research and innovation in Europe.
Catalonia hosts 113 ERC grantees in
the life sciences and healthcare, one
of the highest ratios in Europe.
The European Research Council (ERC)
provides Europe’s most prestigious
and well-funded research grants.
In 2020, 71% of Spain’s new ERC
Advanced Grants have come to Catalonia.
Source: CORDIS, UNiCS (SIRIS Academic), Biocat. [Population] BEL=11,6M SWE=10M AUT= 9M CAT=7,5M DNK=5,8M FIN=5,5M IRL=4,9MCatalan institutions run excellent ERC PoC grants in the
life sciences and healthcare
translational research, advancing
rapidly towards commercialisation CATALONIA 1st (26)
BELGIUM 2nd (15)
TRANS-
LATIONAL
PROOF OF BUSINESS
FORMATION
BUSINESS SWEDEN 3rd (13)
CONCEPT GROWTH
RESEARCH / LICENSING
FINLAND 4th (11)
IRELAND 5th (10)
The ERC Proof of Concept provides funding to bring ideas with
commercial potential to a pre-demonstration stage, de-risking new AUSTRIA 6th (9)
technologies to commercial partners and investors.
DENMARK 7th (6)
Source: CORDIS, SIRIS Academic.+400 deep tech
companies
Biotech Digital Health CS*/ICT KETs**
Genomics Bioinformatics Artificial Intelligence Robotics
Synthetic biology Digital Therapeutics Big Data & Analytics Electronics
3D&Bio Printing Telehealth IoT Photonics
Immunotherapies Blockchain Nanotechnology
RNA Therapies AR/VR Advanced Materials
Talented founders, with extensive
pharma, clinical and research expertise
Source: Biocat. *Computer Science **Key Enabling TechnologiesA dynamic
product
pipeline
BioRegion companies
have 41 drugs and
therapies in clinical
development,
covering a wide range
of therapeutic areas.
Source: Biocat.In a world-class environment for clinical research
Number of active clinical trials Top pharma companies developing
clinical trials in Catalonia
#7 in the EU #13 worldwide
Source: Clinicaltrials.gov, SIRIS Academic.And the best supporting research infrastructures
Barcelona National Center Fully-equipped science and
Alba Synchrotron
Supercomputing Center for Genomic Analysis business parksThe right time to invest
x4
VC/PE investment growth World-class life sciences
in the last 5 years research and startups
(over the previous period)
A great investment opportunity
in Barcelona life sciences and healthcare startupsGenerous tax incentives
CORPORATE TAX SOCIAL SECURITY PATENT BOX PERSONAL INCOME TAX
EXEMPTION FOR NON-RESIDENTS
Up to Bonuses of Up to Flat rate at
59% for R&D
40% 60% 24%
for R&D staff of licensing during the first
expenses
income exempted 6 years
Source: ACCIO. More information: http://catalonia.com/.content/documents/RDIncentives_tcm213-241073.pdfTailored support for foreign investors
● Accelerated introduction to local business ● Site selection and temporary spaces
practices and regulations (tax, corporate, labor,
immigration law) ● Talent recruitment
● Company incorporation, permits and ● Reliable suppliers and business partners
paperwork
● Networking
● Financing and incentives
Contact point: comunicacio@biocat.cat Investment support services:Browse and explore investment opportunities Catalan Life Sciences Database http://www.catalanlifesciences.com/
[Annexes] Ecosystem overview LS&H multinationals - Innovation centers - Map of main actors Selected case studies Biotech Medtech Digital Health Ability Pharma Anaconda Biomed Mediktor Minoryx Therapeutics Glycardial Diagnostics Psious Ona Therapeutics STAT-DX QMENTA Peptomyc Pulmobiotics
A European
life sciences and healthcare
business hub
Source: BiocatInnovation centers
recently set up in Barcelona
(2018-20)
Source: BiocatA rich ecosystem,
Map of main actors
at a walking distance
Source: BiocatFOUNDED: 2009 Developing advanced cancer therapies that
SECTOR:
are based upon autophagy, suitable as
Biotechnology monotherapy or as first-line therapy.
2010: Seed Round (€1.5m; Founders)
EXPERTISE / SPECIALITY / FOCUS:
Oncology 2012: pre-Series A (€1m; Inveready, Genoma España)
2019: Series A (€3.5m; Inveready, Everis)
STAGE:
2020: SME Instrument II (€2.5m; European Commission)
Clinical Phase II European Investment Bank (€2.5m)
INTELLECTUAL PROPERTY Founders: Maribel Bergés Fraile (CEO)
1 worldwide patent Institutions: Autonomous University of Barcelona (UAB)FOUNDED: 2011 Developing new therapies with an unique
SECTOR:
mechanism of action for rare central nervous
Biotechnology system diseases of genetic origin.
2013: Series A (€1.5m; Caixa Capital Risc, Inveready, Mineco, Acció)
EXPERTISE / SPECIALITY / FOCUS:
Orphan CNS Diseases 2015: Series B (€20m; Ysios, Kurma partners, Roche Ventures, Chiesi
Ventures, Indivest partners, Caixa Capital Risc, HealthEquity,
Sanfilippo foundation)
STAGE: 2018: Series B II (€22m; Fund+, Federal holding and investment group,
Clinical Phase III Société Régionale d’investissement, Sambrinvest)
SME Instrument II (€3.1m, European Commission)
Founders: Joan Aymamí & Xavier Barril
Institutions: University of Barcelona (UB)
Institute of Research and Advanced Studies (ICREA)FOUNDED: 2019 Developing specialized therapeutic biologics
SECTOR:
targeting tumor metastatic-initiating cells
Biotechnology and lipid metabolism.
EXPERTISE / SPECIALITY / FOCUS:
Oncology
2019: Seed round (€1.5m; Asabys Partners )
STAGE: 2020: Serie A (€30m, Asabys Partners, Alta Life Sciences, Bpifrance
Preclinical Fund+, Ysios Capital)
Founders: Valerie Vanhooren (CEO) & Salvador Aznar (CSO)
Institutions: Institute for Research in Biomedicine (IRB)
Institute of Research and Advanced Studies (ICREA)FOUNDED: 2014 Developing Omomyc, a new generation of cell
SECTOR:
penetrating peptides targeting the Myc
Biotechnology oncoprotein against a wide range of tumors.
2016: Seed Round (€1m; HealthEquity)
EXPERTISE / SPECIALITY / FOCUS:
SME Instrument I (€50k; European Commission, )
Oncology
2017: Series A (€4m; Alta LS, HealthEquity)
STAGE: 2019: SME Instrument II (€2.2m; European Commission)
Preclinical 2020: Looking for Series B to finish clinical phase I/II
INTELLECTUAL PROPERTY Founders: Laura Soucek (CEO) & Marie-Eve Beaulieu
4 worldwide patents Institutions: Vall d’Hebron Institute of Oncology (VHIO)
Institute of Research and Advanced Studies (ICREA)FOUNDED: 2020 Developing a novel biotherapeutic
SECTOR:
platform able to expose antigens or
Biotechnology deliver therapeutic agents in the lung in a
controlled, local and continuous manner.
EXPERTISE / SPECIALITY / FOCUS:
Infectious Diseases
STAGE:
2020: Seed round (€2m; Invivo Ventures)
Preclinical
Founders: Maria Lluch (CSO) & Luis Serrano (Advisor)
Institutions: Centre of Genomic Regulation (CRG)FOUNDED: 2015 Developing next generation catheters to
SECTOR:
perform mechanical thrombectomies safely
Medical Technology and efficiently.
EXPERTISE / SPECIALITY / FOCUS:
Cardiovascular
2017: Series A (€15m; Ysios, Omega funds, Innogest, Banc Sabadell)
STAGE:
2018: EIT Health Headstart Funding
Clinical Validation
2020: Series B (Asabys, Banc Sabadell, Innogest, Omega funds)
Founders: Ofir Arad, Marc RibóFOUNDED: 2017 Developing a novel in vitro diagnostic device
SECTOR:
for the early diagnosis of cardiac ischemic
Medical Technology events to reduce the impact of the disease
on patients' life.
EXPERTISE / SPECIALITY / FOCUS:
Cardiovascular 2017: Series A (€2.4m; Caixa Capital Risc, Healthequity)
2018: SME Instrument I & EIT Health Headstart funding (European
STAGE: Commission, €490k)
Clinical Validation 2019: SME Instrument II (1.9M€; European Commission)
Founders: Judit Cubero (CEO) & Lina Badimon (CSO)
Institutions: Catalan Institute of Cardiovascular Sciences (ICCC)
Spanish National Research Council (CSIC)FOUNDED: 2010 Developing and manufacturing molecular
SECTOR:
and immunoassay diagnostics systems for
Medical Technology decentralized clinical testing.
2011: Series A (€2m, Ysios, Axis)
EXPERTISE / SPECIALITY / FOCUS:
Diagnostics 2013: Series B (€17m; Kurma, Indivest, Boehringer venture, Caixa
Capital Risc, Ysios, axis)
2016: Series B II (€29.1m; Glide, Ysios, Kurma, Caixa Capital Risc;
Boehringer, Axis, Indivest, Siemens, Philips)
2017: European Investment Bank (€20m)
2017: Exit (€154m; Qiagen)
Founders: Jordi Carrera, Rafel BruFOUNDED: 2011 Developing an AI-based medical assistant
SECTOR:
that relates patient’s symptoms with
Digital Health possible conditions, giving
recommendations on what to do next.
EXPERTISE / SPECIALITY / FOCUS:
Telehealth
STAGE: 2011: Seed Round (€1.6m, Local B.A.)
Class I Certified 2018: Series A (€3m; Alta, Castel, Naos)
Medical Device 2020: Looking for series B
Founders:Cristian Pascual (CEO), Dr. Oscar Garcia (CMO),
Roger Forcada (CTO) & Josep Carbó (CBDO)FOUNDED: 2013 Developing virtual reality-based solutions for
SECTOR:
therapeutic use in the clinical practice of
Digital Health mental health conditions.
EXPERTISE / SPECIALITY / FOCUS:
Mental and behavioural
disorders 2015: Seed Round (€1m; Rothenberg, Caixa Capital Risc)
STAGE: 2016: SME Instrument II (European Commission, €600k)
Validation Trials 2019: Series A (€8m; Asabys, Caixa Capital Risc, CG Health Ventures,
Bstartup)
Founders: Xavier Palomer (CEO) & Victor García (CTO)FOUNDED: 2013 Developing medical image processing
SECTOR:
algorithms through AI, in order to accelerate
Digital Health the development of new therapies for
neurological diseases.
EXPERTISE / SPECIALITY / FOCUS:
Drug Development
2014: Seed round (€160k; crowdfunding)
2017: Series A (€2.7m; Business Angels) & SME Instrument I (€50k)
2018: SME Instrument II (€300k)
2020: Series A II (€1.4m; crowdfunding)
Founders:Landon McKenna (CCO), Vesna Prchkovska (COO) &
Paulo Rodrigues (CTO)Barcelona The BioRegion of Catalonia www.bioregioncatalonia.com #BioRegionCatalonia
You can also read
